BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy (ATTR ...

BridgeBio Pharma BBIO recently received FDA approval for its pipeline candidate acoramidis for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...

Citi analyst David Lebowitz keeps a Buy rating on BridgeBio (BBIO) with a $45 price target after the FDA granted approval for Attruby for ATTR-CM. The drug’s label was in line with expectation ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

Below is Validea's guru fundamental report for BRIDGEBIO PHARMA INC (BBIO). Of the 22 guru strategies we follow, BBIO rates highest using our Contrarian Investor model based on the published ...

Oncternal Therapeutics (ONCT), 910% surge in interest Scholar Rock (SRRK), 839% surge in interest Cabaletta Bio (CABA), 328% surge in interest Cassava Sciences (SAVA), 324% surge in interest ...

Bullish option flow detected in BridgeBio (BBIO) Pharma with 2,983 calls trading, 1.0x expected, and implied vol increasing over 2 points to 132.22%. Dec-24 30 calls and Dec-24 35 calls are the ...